TASCOM Co.,Ltd.
KKRX:3360403,900.00
KRW
+100.00
(+2.63%)
ISIN
KR7336040001
Return %
Stock
S&P 500
1Y
-9.30
13.14
3Y
-59.37
80.78
5Y
-84.08
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- In-Geun Lee
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Anyang-si South Korea
- IPO Date
- Dec 2, 2019
- Website
- tascom.org
- Similar Companies
- Business
- TASCOM Co.,Ltd. is a South Korea-based biotechnology and medical technology company primarily engaged in the development, manufacturing, and commercialization of advanced regenerative medicine solutions, cell therapies, and specialized biomedical devices. The company operates through key business segments comprising Cell Therapy Development, Diabetes Cellular Therapeutics, Medical Devices and In Vitro Diagnostics, and Biomedical Contract Services. TASCOM Co.,Ltd. offers a comprehensive portfolio of products and services, including stem cell-based regenerative therapy platforms for degenerative and inflammatory indications; bio-artificial pancreas technologies and pancreatic islet cell transplantation solutions for the treatment of insulin-dependent diabetes; automated cell isolation, expansion, and cryopreservation systems; clinical-grade cell processing consumables, culture media, and biological reagent kits; point-of-care testing (POCT) diagnostic devices and immunoassay kits; and custom contract research and development (CRO) and cell manufacturing services for biopharmaceutical institutions. The company serves university hospitals, specialized clinics, medical research organizations, and biotechnology firms across South Korea and select international markets. In recent developments, TASCOM Co.,Ltd. has advanced the preclinical and clinical validation of its proprietary cell-derived diabetes therapeutic pipeline, expanded its Good Manufacturing Practice (GMP) compliant cell therapy production facilities to enhance commercial-scale output, and formed strategic research alliances with domestic academic medical centers to co-develop next-generation bio-convergence organ replacement platforms. Furthermore, the company has secured institutional capital to finance ongoing clinical trials and research operations while actively executing strategic reorganization initiatives to pursue a transfer listing from the Korea New Exchange (KONEX) to the KOSDAQ market. Founded in 2014, TASCOM Co.,Ltd. is headquartered in Seongnam-si, Gyeonggi-do, South Korea.